Contract awarded for products that bring improvement to healthcare industry LOS GATOS, Calif., Jan. 13, 2026 – Tulavi Therapeutics announced its allay™ Hydrogel Cap has received
We are pleased to announce the publication of the first peer-reviewed clinical data on the allay™ Hydrogel Cap in Plastic and Reconstructive Surgery, Global Open. This paper, titled “”A Novel Hydrogel for Treatment and Prevention of Symptomatic Neuroma: Early Clinical Experience,” is an important step forward in building evidence-based solutions that improve care for patients undergoing peripheral nerve surgery. Importantly, these findings replicate the safety and efficacy demonstrated in preclinical studies and reported in early clinical experience.
LOS GATOS, Calif., Oct. 7, 2025 /PRNewswire/ — Tulavi Therapeutics, a private medical technology company focused on advancing surgical solutions that address critical unmet needs in peripheral
3 Filters That Separate Breakthrough Devices from Failed Ventures
What truly sets successful medtech apart? Josh Vose, CEO of Tulavi Therapeutics, shares three key lessons from his journey, from focusing only on devices that matter, to choosing the harder regulatory path that builds lasting advantage, to tailoring pitches to the right investors. His perspective offers a clear view into what it takes to move from idea to adoption.
LOS GATOS, Calif., Aug. 26, 2025 /PRNewswire/ — Tulavi Therapeutics has been selected to exhibit the allay™ Hydrogel Cap, a first-of-its-kind surgical device designed to protect
LOS GATOS, Calif., July 23, 2025 /PRNewswire/ — Tulavi Therapeutics, a private medical technology company focused on advancing surgical solutions that address critical unmet needs in peripheral nerve surgery
Veteran medtech executive brings proven track record of scaling innovative medical device companies and successful exits LOS GATOS, Calif., June 18, 2025 /PRNewswire/ — Tulavi Therapeutics, Inc. (“Tulavi”), a medical device company transforming peripheral nerve surgery with its Adaptive Hydrogel Technology, today announced the appointment of Raymond W. Cohen to serve as Vice Chairman of its Board of Directors. “We are thrilled to welcome Ray to our Board of Directors at this pivotal moment in Tulavi’s growth trajectory,” said Josh Vose MD, CEO of Tulavi Therapeutics. “Ray brings to our board an exceptional track record of building and scaling innovative medical device companies, combined with his deep understanding of hydrogels, neurology, and device markets.